logo

CLB

Core Laboratories·NYSE
--
--(--)
--
--(--)
5.10 / 10
Netural

Analysis concludes modest fundamental quality (5.1/10). Favorable components: Net cash flow from operating activities / Total liabilities (%) and PB-ROE, whereas limitations surface in Net assets per share (growth rate compared to beginning of year %) and Profit-MV. Investment recommendation: guarded.

Fundamental(5.1)SentimentTechnical

Analysis Checks(6/10)

Net assets per share (growth rate compared to beginning of year %)
Value9.41
Score1/3
Weight3.19%
1M Return1.79%
Net profit attributable to parent company shareholders / Net profit (%)
Value97.86
Score2/3
Weight4.76%
1M Return2.38%
Net cash flow from operating activities / Operating revenue (%)
Value7.49
Score0/3
Weight-2.29%
1M Return-1.46%
Profit-MV
Value0.60
Score0/3
Weight0.38%
1M Return0.26%
Net income-Revenue
Value-0.34
Score0/3
Weight5.04%
1M Return2.91%
PB-ROE
Value-0.07
Score2/3
Weight17.27%
1M Return6.92%
Cash-UP
Value-0.91
Score2/3
Weight20.80%
1M Return7.74%
Net cash flow from operating activities / Total liabilities (%)
Value0.09
Score3/3
Weight13.33%
1M Return6.73%
Asset-MV
Value-0.51
Score3/3
Weight18.81%
1M Return7.59%
Cash-MV
Value-0.89
Score3/3
Weight18.71%
1M Return8.09%
Is CLB fundamentally strong?
  • CLB scores 5.10/10 on fundamentals and holds a Fair valuation at present. Backed by its 11.83% ROE, 6.18% net margin, 27.17 P/E ratio, 3.09 P/B ratio, and 2.99% earnings growth, these metrics solidify its Netural investment rating.